HCM vs. HIK, INDV, AMYT, BMK, APH, BXP, AGY, ANCR, EAH, and CEL
Should you be buying HUTCHMED stock or one of its competitors? The main competitors of HUTCHMED include Hikma Pharmaceuticals (HIK), Indivior (INDV), Amryt Pharma (AMYT), Benchmark (BMK), Alliance Pharma (APH), Beximco Pharmaceuticals (BXP), Allergy Therapeutics (AGY), Animalcare Group (ANCR), ECO Animal Health Group (EAH), and Celadon Pharmaceuticals (CEL). These companies are all part of the "drug manufacturers - specialty & generic" industry.
HUTCHMED (LON:HCM) and Hikma Pharmaceuticals (LON:HIK) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, community ranking, dividends, risk, institutional ownership, media sentiment and analyst recommendations.
35.4% of HUTCHMED shares are held by institutional investors. Comparatively, 37.6% of Hikma Pharmaceuticals shares are held by institutional investors. 42.9% of HUTCHMED shares are held by insiders. Comparatively, 30.6% of Hikma Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, HUTCHMED and HUTCHMED both had 1 articles in the media. Hikma Pharmaceuticals' average media sentiment score of 0.91 beat HUTCHMED's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the news media.
HUTCHMED has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, Hikma Pharmaceuticals has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500.
Hikma Pharmaceuticals has a consensus price target of GBX 2,050, suggesting a potential upside of 6.00%. Given Hikma Pharmaceuticals' higher possible upside, analysts plainly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.
HUTCHMED has a net margin of 12.03% compared to Hikma Pharmaceuticals' net margin of 6.61%. HUTCHMED's return on equity of 14.65% beat Hikma Pharmaceuticals' return on equity.
Hikma Pharmaceuticals received 602 more outperform votes than HUTCHMED when rated by MarketBeat users. However, 78.40% of users gave HUTCHMED an outperform vote while only 70.56% of users gave Hikma Pharmaceuticals an outperform vote.
Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.
Summary
Hikma Pharmaceuticals beats HUTCHMED on 9 of the 16 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding HCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HUTCHMED Competitors List
Related Companies and Tools
